190 related articles for article (PubMed ID: 36912150)
1. Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer.
Xu T; Li J; Wang Z; Zhang X; Zhou J; Lu Z; Shen L; Wang X
Cancer Med; 2023 May; 12(9):10473-10484. PubMed ID: 36912150
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
[TBL] [Abstract][Full Text] [Related]
3. Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in
Tsai HL; Huang CW; Chen YC; Su WC; Chang TK; Chen PJ; Li CC; Chang YT; Wang JY
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138211
[No Abstract] [Full Text] [Related]
4. Impact of Metastasectomy in the Multimodality Approach for
Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
[TBL] [Abstract][Full Text] [Related]
5. Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China.
Xu Y; Wang G; Zheng X; Chang W; Fu J; Zhang T; Lin Q; Lv Y; Zhu Z; Tang W; Xu J
Eur J Surg Oncol; 2023 Nov; 49(11):106981. PubMed ID: 37455182
[TBL] [Abstract][Full Text] [Related]
6. Real-world first-line treatment of patients with BRAF
Martinelli E; Cremolini C; Mazard T; Vidal J; Virchow I; Tougeron D; Cuyle PJ; Chibaudel B; Kim S; Ghanem I; Asselain B; Castagné C; Zkik A; Khan S; Arnold D
ESMO Open; 2022 Dec; 7(6):100603. PubMed ID: 36368253
[TBL] [Abstract][Full Text] [Related]
7. Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States.
Trunk A; Braithwaite M; Nevala-Plagemann C; Pappas L; Haaland B; Garrido-Laguna I
J Natl Compr Canc Netw; 2022 Feb; 20(2):144-150. PubMed ID: 35130499
[TBL] [Abstract][Full Text] [Related]
8. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
[TBL] [Abstract][Full Text] [Related]
9. Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study.
Meng Q; Zhao J; Yu Y; Wang K; Ren J; Xu C; Wang Y; Wang G
BMC Cancer; 2023 Feb; 23(1):191. PubMed ID: 36849918
[TBL] [Abstract][Full Text] [Related]
10. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
11. Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx).
Bruera G; Cannita K; Di Giacomo D; Lamy A; Frébourg T; Sabourin JC; Tosi M; Alesse E; Ficorella C; Ricevuto E
BMC Med; 2013 Mar; 11():59. PubMed ID: 23497191
[TBL] [Abstract][Full Text] [Related]
12. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments.
Ros J; Matito J; Villacampa G; Comas R; Garcia A; Martini G; Baraibar I; Saoudi N; Salvà F; Martin Á; Antista M; Toledo R; Martinelli E; Pietrantonio F; Boccaccino A; Cremolini C; Dientsmann R; Tabernero J; Vivancos A; Elez E
Ann Oncol; 2023 Jun; 34(6):543-552. PubMed ID: 36921693
[TBL] [Abstract][Full Text] [Related]
13. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain.
Martínez-Lago N; Fernández-Montes A; Covela M; Brozos EM; De la Cámara J; Méndez Méndez JC; Jorge-Fernández M; Cousillas Castiñeiras A; Reboredo C; Arias Ron D; Pellón Augusto ML; González Villarroel P; Graña B; Salgado Fernández M; Carral Maseda A; Vázquez Rivera F; Candamio Folgar S; Reboredo López M;
BMC Cancer; 2021 Jan; 21(1):64. PubMed ID: 33446148
[TBL] [Abstract][Full Text] [Related]
14. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).
Goldstein J; Tran B; Ensor J; Gibbs P; Wong HL; Wong SF; Vilar E; Tie J; Broaddus R; Kopetz S; Desai J; Overman MJ
Ann Oncol; 2014 May; 25(5):1032-8. PubMed ID: 24585723
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of
de la Fouchardière C; Cohen R; Malka D; Guimbaud R; Bourien H; Lièvre A; Cacheux W; Artru P; François E; Gilabert M; Samalin-Scalzi E; Zaanan A; Hautefeuille V; Rousseau B; Senellart H; Coriat R; Flippot R; Desseigne F; Lardy-Cleaud A; Tougeron D
Oncologist; 2019 Dec; 24(12):e1331-e1340. PubMed ID: 31152084
[TBL] [Abstract][Full Text] [Related]
16. A validated prognostic classifier for
Loupakis F; Intini R; Cremolini C; Orlandi A; Sartore-Bianchi A; Pietrantonio F; Pella N; Spallanzani A; Dell'Aquila E; Scartozzi M; De Luca E; Rimassa L; Formica V; Leone F; Calvetti L; Aprile G; Antonuzzo L; Urbano F; Prenen H; Negri F; Di Donato S; Buonandi P; Tomasello G; Avallone A; Zustovich F; Moretto R; Antoniotti C; Salvatore L; Calegari MA; Siena S; Morano F; Ongaro E; Cascinu S; Santini D; Ziranu P; Schirripa M; Buggin F; Prete AA; Depetris I; Biason P; Lonardi S; Zagonel V; Fassan M; Di Maio M
Eur J Cancer; 2019 Sep; 118():121-130. PubMed ID: 31330487
[TBL] [Abstract][Full Text] [Related]
17. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
18. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.
Atreya CE; Greene C; McWhirter RM; Ikram NS; Allen IE; Van Loon K; Venook AP; Yeh BM; Behr SC
J Natl Compr Canc Netw; 2016 Dec; 14(12):1536-1543. PubMed ID: 27956538
[TBL] [Abstract][Full Text] [Related]
19. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
[TBL] [Abstract][Full Text] [Related]
20. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
Grothey A; Fakih M; Tabernero J
Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]